Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bangavax
- Development stage
- Unknown
- Lead developer
- Globe Biotech
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Bangavax (also known as BANCOVID) is an mRNA-based COVID-19 vaccine developed by Globe Biotech Limited, a Bangladeshi pharmaceutical company. The vaccine utilizes a proprietary nanotechnology-based platform to deliver mRNA that encodes the SARS-CoV-2 spike protein, thereby eliciting a protective immune response. It is designed as a single-dose vaccine and has demonstrated efficacy against multiple variants of the virus in preclinical studies. Bangavax is notable for being the first pharmaceutical product from Bangladesh to receive a US patent for its delivery technology, covering its nanotechnology platform. The vaccine was included in the World Health Organization's list of COVID-19 vaccine candidates in 2020 and has undergone preclinical testing in non-human primates before entering Phase 1 clinical trials.
- Brand names
- Bangavax
- Other names
- BANCOVID
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on Bangavax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bangavax.